

**Empower Your Family's Future: Screen Smart, Plan Safe** 

## 🎎 eurofins

Genoma



of couples are at increasing **HEALTHY CARRIERS OF GENETIC** 2-5% risk to have an affected baby. DISEASES ARE INDIVIDUALS WITH **NO OVERT PHENOTYPE BUT** CARRYING GENETIC VARIANT(S) live births are affected bv 30/10.000 WITHIN A DISEASE-GENE. autosomal recessive (AR) and X-linked (XR) diseases<sup>1</sup> **Autosomal Recessive Inheritance:** both parents are carriers Both females and males may be affected or carriers Carrie (no sex ratio) • Affected people have two mutations: one on each copy of the gene (homozygous or compound heterozygous) Carriers have only one mutation (heterozygous) Both parents heterozygous (carriers): 1/4 (25%) risk of affected child Unaffected Affected child 25% 50% 25% X-Linked Recessive Inheritance: carrier mother Unaffect fathe Carrier Males are affected while females are carriers mother Affected males have one mutation on their X chromosome mutated gene (hemizygous) Carrier mothers have only one mutation (heterozygous) Carrier mother: 1/4 (25%) risk of affected child (50% of males) Only females will be tested for XL conditions Affected Carrier daughte 25% 25% 25% 25%

## Carrier screening test enables to identify couples at an elevated risk of having affected pregnancies.

Carrier screening (CS) is a genetic test applicable to individuals and couples within their **reproductive age.** This screening involves examining disease-causing pathogenic variants in autosomal genes for both members of the couple (for autosomal recessive diseases) or in a gene on the X chromosome for the female partner (for X-linked recessive diseases).



Number 691 • March 2013

nittee on Genetics

**COMMITTEE OPINION** 

American College of Obstetricians and Rink, MD: Stephanie Romero, MD: Io

"Carrier screening and genetic counseling ideally should be performed before pregnancy because this enables couples to learn about their reproductive risk and consider the most complete range of reproductive options." ACOG Clinical Guidelines



**Genescreen** is the carrier screening test developed by Eurofins Genoma and conducted **using Next Generation Sequencing.** 

Selection of conditions and genes is based on:

- CARRIER FREQUENCY
- PENETRANCE
- CLINICAL CORRELATION OF PHENOTYPE TO GENOTYPE
- GUIDELINES OF MAJOR HUMAN GENETICS AND REPRODUCTIVE SOCIETIES

• Cystic Fibrosis (CFTR)

- Spinal muscular atrophy (SMN1)
- Fragile-X syndrome (FMR1)
- a-Thalassemia (HBA1)
- a-Thalassemia (HBA2)
- β-thalassemia and Sickle cell anemia (HBB)
- Xeroderma pigmentosum (XPC)
- Oculocutaneous albinism type 1A and type 1B (TYR)
- Phenylketonuria (PAH)
- Nonsyndromic hearing loss recessive 1A (GJB2)

PANELS AVAILABLE	Focus	Protect	Easy-Donor	Complete
N genes analysed	>30	>120	>400	>2000
N pathologies analysed	>30 AR/XL	>140 AR/XL	>450 AR/XL	>2100 AR/XL
Who is the test indicated for?	General couples	General couples	Donors	Consanguineous pregnancies couples with family or medical history
		Panel designed on: ACMG Practice Resource <sup>2</sup> SEF Recommandation <sup>3</sup> ACOG Guidelines <sup>4</sup>	Panel alligned with the IVF program of different Countries	Compatible with the majority of panels currently available in the market

## CARRIER TEST CUSTOMIZABLE ACCORDING TO SPECIFIC NEEDS

#### Matching

The option to compare screening test results between the two partners (or donor and recipient), assessing the risk of inheriting diseases in the future child.

#### Extension





#### Customization

Flexibility to personalize the panel based on patient/couple needs.



### When is the test indicated?

- During or before pregnancy (pre-conceptional or prenatal testing).
- During the reproductive age: all women and their reproductive partners, as well as to gamete (egg or sperm) donors.
  Partners may be tested at the same time or at different moments after one of them tested
- Consanguinity and positive family history are indications for
- pre-conceptional/prenatal carrier screening but genetic counselling is recommended.

#### How to perform Genescreen tests?

positive (contextual or sequential approach).











Sample collection of BLOOD

Shipping to Eurofins Genoma Lab



Detailed Test Report IN 20 WORKING DAYS

# Consult the complete list of analysed genes on the website www.familyproject.it



Genoma

#### References:

- 1. Capalbo A, at al. Considerations on the use of carrier screening testing in human reproduction: comparison between recommendations from the Italian Society of Human Genetics and other international societies. J Assist Reprod Genet. 2022 Nov;39(11):2581-2593. doi: 10.1007/s10815-022-02653-3. Epub 2022 Nov 12.
- 2. Miller DT, Lee K, Abul-Husn NS, Amendola LM, Brothers K, Chung WK, Gollob MH, Gordon AS, Harrison SM, Hershberger RE, Klein TE, Richards CS, Stewart DR, Martin CL; ACMG Secondary Findings Working Group. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023 Aug;25(8):100866. doi: 10.1016/j.gim.2023.100866. Epub 2023 Jun 22.
- 3. Abellàn-Garcìa Sanchèz F., Alamà Faubel P., Aura Masip M., Bassas Arnau L., Castilla Alcalà J.A., Clùa Obrado E., De La Fluente Hernàndez L.A., Guillèn Quilez J.J., Manau Trullàs D., Ruenda J., Ruiz Jorro M., Vendrell Montòn X., Cribado genético en DONACIÓN de GAMETOS. SEF
- 4. Genetic carrier screening. Royal Australian and New Zealand College of Obstetricians and Gynaecologists, RANZCOG. 2022.





#### ROME

Registered Office and Molecular Diagnostics Laboratory Via Castel Giubileo, 11 Laboratory for Medical Genetics and Molecular Diagnostics Sampling and Counselling Via Castel Giubileo, 62

#### MILAN

Laboratory for Medical Genetics and Molecular Diagnostics Sampling and Counselling Via Enrico Cialdini, 16 (Affori Center)

